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CHD1 and CHD2 influences chromatin accessibility
and histone H3 and H3.3 occupancy at active
chromatin regions
Lee Siggens, Lina Cordeddu, Michelle Rönnerblad, Andreas Lennartsson† and Karl Ekwall*†Abstract
Background: CHD1 and CHD2 chromatin remodeling enzymes play important roles in development, cancer and
differentiation. At a molecular level, the mechanisms are not fully understood but include transcriptional regulation,
nucleosome organization and turnover.
Results: Here we show human CHD1 and CHD2 enzymes co-occupy active chromatin regions associated with
transcription start sites (TSS), enhancer like regions and active tRNA genes. We demonstrate that their recruitment is
transcription-coupled. CHD1 and CHD2 show distinct binding profiles across active TSS regions. Depletion of CHD1
influences chromatin accessibility at TSS and enhancer-like chromatin regions. CHD2 depletion causes increased
histone H3 and reduced histone variant H3.3 occupancy.
Conclusions: We conclude that transcription-coupled recruitment of CHD1 and CHD2 occurs at transcribed gene
TSSs and at intragenic and intergenic enhancer-like sites. The recruitment of CHD1 and CHD2 regulates the architecture
of active chromatin regions through chromatin accessibility and nucleosome disassembly.
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ATP-dependent chromatin remodeling enzymes disrupt
DNA-histone interactions facilitating nucleosome mobi-
lization, including the disassembly, eviction, sliding and
spacing of nucleosomes [1]. The ability of ATP-dependent
chromatin remodeling enzymes to manipulate nucleo-
somes also facilitates diverse chromatin-associated pro-
cesses including transcription, DNA repair, incorporation
of histone variants, DNA methylation, the covalent modi-
fication of histone tails and gene activation or silencing
[2]. All ATP-dependent chromatin remodeling enzymes
contain a SNF2-like helicase domain [3]. The chromodo-
main helicase DNA binding protein (CHD) subfamily of
ATP-dependent chromatin remodeling enzymes are char-
acterized by the presence of dual chromatin organization* Correspondence: karl.ekwall@ki.se
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unless otherwise stated.modifier (chromo) domains N-terminal to the SNF2
domain [4]. Human CHD1 and CHD2 are grouped as
subclass I CHD remodelers based on both their modular
organization, with N-terminal dual chromodomains and
on their sequence similarity within the SNF2 helicase
domain in relation to CHD1 homologues in other or-
ganisms [3,5]. In contrast, other human CHD family
remodelers are grouped into class II and class III CHD
proteins on the basis of additional regulatory domains
such as plant homeobox domains as well as protein se-
quence differences in the SNF2 helicase domain [3,5].
Mammalian CHD1 has important biological roles in
stem cell function, prostate cancer and transcription,
while CHD2 has emerged as an important regulator of
genetic stability, development, kidney function, muscle
cell and hematopoietic differentiation [6-15]. In model
organisms, studies on CHD1 homologues have demon-
strated various mechanistic roles in nucleosome disassem-
bly, histone turnover, nucleosome spacing, transcriptionl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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assembly and deposition of the histone H3 variant
H3.3 during development [10,16-19]. Relatively little is
known about CHD2 function on a molecular level with
the exception of muscle cell differentiation where it
was demonstrated that CHD2 is an essential cofactor
for the transcription factor MyoD in H3.3 deposition
at muscle cell gene promoters [12].
Interestingly, CHD family remodelers function as
chromatin readers in some cases by recognizing specific
histone modifications [4]. For example human CHD1
has specific affinity for histone 3 (H3) tails when di- or
tri-methylated at lysine 4 (H3K4me2 and H3K4me3)
[20]. The role of H3K4me2/3 in the physical recruitment
of CHD1 per se is not clear although both are present at
transcribed gene promoters [4]. For example, some studies
have demonstrated that CHD1 recruitment is at least
partially independent of the chromodomains [21,22],
while other studies have linked CHD1 to chromatin
associated with transcriptional elongation [23-25]. In
the model organisms, budding yeast and Drosophila,
CHD1 homologues do not show any specific affinity for
H3K4me2/3 and bind unmodified H3 [20,21].
The fission yeast CHD1 homologue Hrp1 was shown
to co-purify with the fission yeast mediator complex
[26]. Consistent with this finding, it was later demon-
strated that mediator-dependent assembly of the pre-
initiation complex in vitro is associated with CHD1
recruitment in mammalian cells [9]. Surprisingly, the latter
study demonstrated CHD1 recruitment to pre-initiation
complexes on both naked DNA and chromatin-based
templates, including chromatin templates with and with-
out H3K4me3 [9]. Unlike CHD1, the chromodomains of
CHD2 do not have specific affinity H3K4me3 [27]. In
mouse and human cells, the myogenic transcription
factor MyoD is sufficient for the recruitment of CHD2
to muscle lineage gene promoters, which may be medi-
ated through a direct interaction between MyoD and
CHD2 [12]. It was also suggested that CHD2 does not
bind to housekeeping genes, but operates as a muscle
specific factor in muscle lineage activation. Thus, exactly
how chromatin remodeling enzymes such as CHD1 and
CHD2 are recruited to target sites remains an open
question.
To examine how subclass I CHD remodelers, CHD1
and CHD2 are recruited and function in human cells,
we first carefully examined the occupancy of each in
relation to chromatin states utilizing data from the
Encyclopedia of DNA Elements (ENCODE) consortium
(http://genome.ucsc.edu/ENCODE/). Closer inspection
of the data demonstrates that neither H3K4me3 nor
micrococcal nuclease (MNase) sensitive DNA at the
NDR is correlated to CHD1 or CHD2. We demonstrate
that both CHD1 and CHD2 are recruited in associationwith the RNA polymerase II (Pol II) machinery to active
chromatin regions. Depletion of CHD1 in human cells
reduces the accessibility of active regions as measured
by DNase sensitivity. We also show that at active chro-
matin regions H3 occupancy is increased following
knockdown of CHD2 suggesting a role in promoting
nucleosome disassembly at active regions genome-
wide. Knockdown of CHD2 also leads to a reduction in
the relative enrichment of H3.3 further supporting a
role for CHD2 in nucleosome turnover. We speculate
that noncoding transcription at regulatory elements
such as promoters, enhancers and active tRNA loci
functions partially to modulate the chromatin environ-
ment through the recruitment and action of transcription
coupled factors such as the remodeling enzymes CHD1
and CHD2.
Results and discussion
Recruitment of CHD1 and CHD2 to promoters is linked to
the Pol II machinery
We analyzed CHD1 and CHD2 occupancy by calculating
the enrichment of CHD1 and CHD2 from ChIP-seq data
in relation to the chromatin states delineated by Ernst
et al. [28]. The chromatin states established by Ernst
et al. were based on ChIP-seq data of combinatorial
patterns of eight histone modifications and the insu-
lator binding protein CTCF [28]. The promoter and
enhancer chromatin states are summarized in Table 1.
In relation to promoter chromatin states; H3K4me2/3
and high H3K9/K27ac define the active promoter state.
The weak promoter state is lower in H3K9/27 ac com-
pared to the active promoter state, and H3K27me3
defines the inactive promoter. Enrichment of CHD1
and CHD2 was strongest at the active promoter chro-
matin state (Figure 1A). In all three cell types examined
for both CHD1 and CHD2, the enrichment observed at
active promoters was significantly higher than at weak or
inactive promoters (Kruskall-Wallis, k = 3, P <0.0001).
Previous studies have demonstrated in model organisms
and human cells that CHD1 remodelers are recruited
to promoters in a gene expression-dependent manner
[29,30]. Importantly, the weak promoter state from the
ENCODE project is also defined by H3K4me2/me3
[28]. This suggested that H3K4 methylation is therefore
not sufficient for recruiting CHD1 to promoters in vivo
since occupancy is strongly reduced or absent at weak
promoters, which are marked by H3K4me2/3.
We hypothesized that the presence and absence of the
Pol II transcription machinery occupancy may explain
the difference in occupancy observed between the active
and weak promoter states respectively. Consistent with
this notion, Pol II was strongly enriched at active pro-
moters only, whereas the H3K4me2/3 levels were compar-
able at both promoter states (Figure 1B). This was also
Table 1 Summary of promoter and enhancer chromatin states identified by Ernst et al. in relation to histone
methylation and acetylation
Chromatin state H3K4me1 H3K4me2 H3K4me3 H3K27me3 H3K9ac H3K27ac
Active promoter + +++ +++ - +++ +++
Weak Promoter ++ +++ +++ - + ++
Inactive promoter ++ +++ ++ +++ - +
Enhancer state 4 +++ +++ ++ - +++ +++
Enhancer state 5 +++ ++ - - + +++
Enhancer state 6 ++ +++ - - - -
Enhancer state 7 ++ - - - - -
The frequency of a given mark at each chromatin state is identified as not present (−; <5% frequency), low (+; 5 to 40% frequency), abundant (++; 40 to 70%
frequency) or highly abundant (+++; 70 to 100% frequency).
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K562 cells at the GALK1 transcription start site (TSS),
(Figure 1C; TSS 1), MNase-sequencing data and ChIP-seq
data showed low nucleosome occupancy and high levels
of H3K4me2/3, yet Pol II, CHD1 and CHD2 were not
bound. In contrast, the TSS and gene body of the highly
transcribed H3F3B (Figure 1C; TSS 2) gene were bound
by Pol II and strongly enriched for the CHD1 and
CHD2 remodelers. The UNK gene TSS (Figure 1C; TSS
3) showed lower levels of Pol II, CHD1 and CHD2 occu-
pancy but abundant H3K4me2/3. Such examples clearly
demonstrated that Pol II levels associate with CHD1 and
CHD2 occupancy, indicating that transcription-coupled
recruitment of CHD1 and CHD2 is important in targeting
the enzymes to active promoters. Morettini et al. demon-
strated that the chromodomains of Drosophila melano-
gaster CHD1 are critical for CHD1 function but not
recruitment and concluded that ChIP-seq studies were
needed to confirm this [21]. Our analysis of human CHD1
provides support for this conclusion. Studies on CHD7,
which is also reported to bind H3K4me2/3, revealed that
CHD7 occupancy occurs on a fraction of H3K4me2/3
sites [31,32]. These studies and the CHD7 data available in
the ENCODE project suggest that CHD7, like CHD1, is
recruited to a fraction of H3K4me2/3 sites independently
of the chromodomain-H3K4me2/3 interaction since at
sites such as weak promoters marked by H3K4me3,
CHD7 is not recruited (see Additional file 1).
CHD remodeling enzymes also contain nonsequence-
specific DNA binding domains, which play important
roles in the regulation of chromatin remodeling. Zentner
et al. hypothesized that this may drive recruitment of
the CHD family of remodeling enzymes to active pro-
moters, where nucleosome disassembly provides naked
DNA [30]. In human cells, the majority of promoters have
CpG islands (CGI), which consist of stretches of abundant
CpG base pairs. Such promoters are MNase sensitive
and are thought to have constitutively lower nucleo-
some occupancies relative to non-CGI promoters inde-
pendently of transcription rates [33]. Thus, in mammaliancells, nucleosome occupancy and transcription can be
partially uncoupled since non-CGI promoters show low
nucleosome occupancy only when highly transcribed,
while CGI promoters are constitutively MNase sensitive
[33]. Grouping of CGI promoters into quintiles of ascend-
ing Pol II occupancy clearly demonstrated that CHD1 and
CHD2 recruitment is correlated to Pol II occupancy at
these sites (Figure 2). Furthermore, despite showing low
nucleosome occupancy in the absence of transcription,
CGI TSSs do not recruit CHD1 or CHD2; that is, the
accessible DNA at these nucleosome-depleted regions
(NDRs) is not sufficient for the recruitment.Recruitment of CHD1 and CHD2 at enhancer-like chromatin
and active tRNA genes
Another chromatin state strongly associated with CHD1
or CHD2 enrichment was enhancer chromatin state 4
(Figure 3A). The enhancer chromatin states defined by
Ernst et al. were identified through combinations of H3K4-
methylation including the enhancer-specific H3K4me1
and histone acetylation (Table 1, Figure 3B). We found
that enhancer state 4, which is distinguished by higher
H3K4me3 and H3K9/27 ac than other enhancer states,
was associated with Pol II, CHD1 and CHD2 enrich-
ment. Other enhancer chromatin states 5 to 7, defined
by lower levels of H3K4 methylation and H3K9/27 ac,
showed weaker enrichment for Pol II, CHD1 and CHD2.
This suggested that transcription of enhancers is coupled
to chromatin remodeling by CHD1 and CHD2. Further-
more it has been demonstrated that a fraction of Pol II
binding sites overlap with a distinct set of RNA polymer-
ase III binding sites including active tRNA genes [34,35].
Such active tRNA genes are bound by BRF1, the transcrip-
tion factor IIIB subunit [36]. Consistent with this, we
found CHD1 and CHD2 were enriched at BRF1 but not at
the alternate Pol III transcription factor, BRF2 binding
sites in K562 cells (see Additional file 2). In this scenario,
BRF2 binding sites function as control Pol III sites that do
not overlap with Pol II binding. This suggests CHD1 and
Figure 1 (See legend on next page.)
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Figure 1 CHD1 and CHD2 are recruited to active but not weak or inactive promoters in association with Pol II. (A) CHD1 and CHD2
occupancy is strongest in the active promoter chromatin state in K562 H1 embryonic stem cell (ESC) and GM12878 cells. CHD1 and CHD2
chromatin immunoprecipitation high throughput sequencing (ChIP-seq) data were normalized to input. Box plots illustrate the median and 25th
to 75th percentile with whisker length determined by the Tukey method. In all cell types examined for both CHD1 and CHD2, enrichment at
active promoters is statistically higher than at weak and inactive promoters (Kruskall-Wallis test with Dunn’s post test correction, k = 3, P <0.0001)
(B) H3K4me2 and H3K4me3 are present at both active and weak promoters, while Pol II enrichment distinguishes the active and weak promoter
chromatin state. (C) Examples of the transcription start site (TSS) of genes marked by H3K4me2/3 with differential Pol II, CHD1 and CHD2 binding.
The GAL1K1 promoter - TSS1 is marked by H3K4me2/3 but is not bound by Pol II, CHD1 or CHD2, while the H3F3B promoter, TSS2, is strongly
bound by Pol II along with CHD1 and CHD2. TSS3 of the UNK gene promoter displays H3K4me2/3 enrichment on a similar scale to the H3F3B
gene but has weaker Pol II, CHD1 and CHD2 binding.
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II transcription occurs, such as tRNAs.
CHD1 and CHD2 show overlapping occupancy but
discrete binding profiles at transcription start sites
To validate the finding that CHD1 and CHD2 both pre-
fer active promoter and enhancer chromatin states we
identified ChIP-seq peaks using model-based analysis for
ChIP-seq (MACS) [37] with a stringent cut-off p value
of 1 × 10−15. For both data sets, peaks were merged if
they fell within approximately one nucleosome length
from another (200 bp). This produced 9,827 CHD1
peaks and 7,736 CHD2 peaks. For CHD1 and CHD2 re-
spectively, 94% and 78% of high confidence peaks fell
within a region associated with the active promoter or
enhancer chromatin state 4 or both, based on chromatin
states defined by Ernst et al. (Figure 4A, Table 1). Since
chromatin states are continuous, a given peak may fall
across more than one chromatin state.
The majority of CHD1 and CHD2 sites overlapped
(60%) (Figure 4B). Despite this, the exact binding profiles
of CHD1 and CHD2 at transcription start sites of genes in
the top expression quintile differed (Figure 4C). CHD1
was enriched in a manner mimicking its preferred
H3K4me2/3 nucleosomal substrates, while CHD2 bound
across the NDR (Figure 4C). For CHD1, we propose
that transcription-coupled recruitment with the Pol IIFigure 2 Recruitment of CHD1 and CHD2 at CpG island (CGI) promote
independently of micrococcal nuclease (MNase) sensitivity. Genes with
quintiles of ascending Pol II occupancy in K562 cells. The average MNase-seq
from −2500 to +2500 bases from the annotated TSS. Light gray lines represen
the third quintile, black the fourth and red the fifth quintile of Pol II occupancmachinery at the pre-initiation complex stage functions
as the primary recruitment mechanism. In support
of this, it is well established that CHD1 interacts with
multiple Pol II-associated complexes [9,22,23,38,39].
Following recruitment, CHD1 then presumably inter-
acts preferentially with H3K4me2/3 marked nucleo-
somes. In contrast, CHD2 does not have any specific
affinity for H3K4me2/3 and binds strongest at the NDR.
An alternative possibility is that differences in cross-
linking preferences could affect the results obtained from
conventional ChIP-seq. Future studies could address this
by using higher resolution techniques, such as those
employed by Skene et al., for murine Chd1 or using
ChIP-exo to gain a more exact chromatin remodeler-
DNA footprint [29,40].
To test if transcription was linked to CHD1 and
CHD2 recruitment, K562 cells were incubated with the
Pol II CTD kinase inhibitor 5,6-dichloro-1-β-D-ribo-
furanosyl-1H-benzimidazole (DRB) to block elongation
and synchronize transcription at the initiation stage
(Figure 5A). This led to an accumulation of Pol II and a
reduced H3 occupancy at the active NPM1 gene pro-
moter as measured by ChIP-qPCR (Figure 5B, Students
t-test, ***P <0.001). The inactive PRSS1 gene promoter
was used as a control. Consistent with the proposed model
of Pol II-driven recruitment, the binding of both CHD1
and CHD2 to the NPM1 gene promoter was significantlyrs correlates with RNA polymerase II (Pol II) occupancy
CGI overlapping the transcription start sites (TSS) were organized into
signal, CHD1 and CHD2 occupancy was then plotted across the region
t the bottom quintile, medium gray the second lowest quintile, dark gray
y.
Figure 3 CHD1 and CHD2 are enriched at an enhancer-like chromatin state with RNA polymerase II (Pol II). (A)The occupancy of CHD1
and CHD2 occurs primarily at enhancer-like chromatin state 4, which also showed the strongest binding by Pol II (Kruskall-Wallis test with Dunn’s
post test correction, k = 3, P <0.0001, comparing enhancer state 4 to all other enhancer-like chromatin states). (B) In contrast H3K4 methylation
was observed to different extents at all enhancer-like chromatin states.
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we conclude that CHD1 and CHD2 are recruited with
the Pol II machinery. The Henikoff laboratory recently
demonstrated that a catalytically inactive, ATPase mutant
of murine Chd1 reduces Pol II release from promoters,
resulting in increased Pol II occupancy at TSSs. Consistent
with our data (Figure 5B) increased Pol II occupancy
in cells expressing mutant Chd1 was associated with in-
creased Chd1 occupancy directly across the TSS [29].
Our findings are also consistent with a recently pub-
lished study showing that budding yeast Chd1 more
closely matches Pol II phosphorylated at Serine 5
across the 5’ regions of genes than it does with the
elongating form phosphorylated at Serine 2 [41]. This
is the case for both human CHD1 and CHD2, which
bind across the 5’ region of genes similar to total Pol II
ChIP-seq data while serine 2 phosphorylated Pol II
shows stronger enrichment at the 3’ end of genes (see
Additional file 3).CHD1 affects chromatin accessibility at transcription start,
intragenic and intergenic sites
To begin to dissect the functions of CHD1 and CHD2
and to confirm that they target active loci such as
promoters and enhancers, we performed siRNA knock-
downs in K562 cells combined with DNase accessibility
assays. Effective knockdown of CHD1 and CHD2
was demonstrated at both mRNA and protein levels
(Additional file 4).
DNase hypersensitivity sites (DHS) define regions of
accessible chromatin associated with TSSs of expressed
genes, while intergenic and intragenic DHS represent
potential enhancer regions associated with transcription
factor binding sites [42]. We analyzed ENCODE DHS
associated with the TSSs of highly expressed genes in
K562 cells (n = 15) as well as intergenic and intragenic
DHS sites (n = 15) and expressed tRNA genes (n = 6),
which overlap DHS sites. Depletion of CHD1 with
siRNA reduced the accessibility of all DHS types tested,
Figure 4 CHD1 and CHD2 co-occupy active promoters but show different binding profiles across the transcription start site (TSS). (A)
Statistically significant high confidence peaks from CHD1 and CHD2 chromatin immunoprecipitation sequencing (ChIP-seq) data were intersected
with chromatin state annotations from K562 cells using model-based analysis for ChIP-seq (MACS) with a stringent cut-off p value of 1 x 10−15.
The majority of CHD1 (94%) and CHD2 (78%) binding sites fall within an active promoter or enhancer chromatin state or both as defined by Ernst et al.
(B) The majority of CHD1 and CHD2 bound sites are overlapping; 60% of the 7,736 CHD2 binding sites overlap with at least one of 9,827 CHD1 peaks.
(C) At highly expressed genes defined in the top 20% expression quintile, CHD1 binding profile follows the enrichment of H3k4me2/3-marked
nucleosomes. In contrast, CHD2 binds strongest across the micrococcal nuclease (MNase) sensitive nucleosome depleted region (NDR) at the TSS.
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***P >0.001, one-way ANOVA). Inaccessible centromeric
repeats were used as a negative control and remained
inaccessible (Figure 6A). The decrease in accessibility of
DHS sites in CHD1 siRNA treated K562 cells was reduced
to less than 10% to more than 90% of control (Figure 6B).
Yet, since all DHS sites tested remained accessible to
DNase to some degree, other factors must operate inde-
pendently of CHD1 to promote accessible chromatin.Furthermore since there are on average more than
200,000 DHS loci per cell type [42], and we only tested
36 DHS sites, this study is not comprehensive. It does
suggest, however, that CHD1 co-operates with other
factors to promote accessible chromatin at regulatory
regions.
DHS are embedded within chromatin marked by
H3K4me2/3 at TSS and at intergenic and intragenic
DHS sites including enhancers [43-46]. One possible
Figure 5 Prolonged RNA polymerase II (Pol II) elongation inhibition leads to an accumulation of Pol II, a reduction in nucleosome
occupancy and recruitment of CHD1 and CHD2. (A) Chromatin immunoprecipitation sequencing (ChIP-seq) data in asynchronous cultures
reflect the complex dynamics associated with cells at different stages of transcription such as the inactive off state, the initiation stage when the Pol II
machinery assembles and the elongation phase following promoter escape. Elongation inhibitor 5,6-dichloro-1-β-D-ribofuranosyl-1H-benzimidazole
(DRB) synchronizes transcription in cells by preventing elongation and promoter escape. (B) Prolonged DRB inhibition results in Pol II accumulation
and H3 depletion at the transcription start site (TSS) of an expressed gene (NPM1) but not inactive gene (PRSS1). Pol II accumulation associates with
increased CHD1 and CHD2 recruitment (significant differences between means of control and DRB tested with the students t-test, ***P <0.001).
Figure 6 CHD1 regulates chromatin accessibility at transcription start site (TSS)-associated, intergenic, intragenic and active tRNA
DNase hypersensitivity sites (DHS). (A-B) Knockdown of CHD1 reduces the accessibility of TSS-associated, intragenic and intergenic DHS sites
in K562 cells. (A) Data showing the accessibility of selected loci representing non-CGI TSS DHS sites (C1ORF159 and HGB1) CGI TSS sites (PIN1 and
H3F3B), intragenic DHS sites (HGB2 and CD19 intra) and two intergenic loci. Centromeric repeats were used as inaccessible controls. Data represent
biological replicates and error bars standard deviation. (B) Mean accessibility values from three biological replicates for each loci tested were plotted as
the percentage of accessibility in control siRNA treated cells. Differences compared to control were tested by one-way ANOVA, **P <0.01, ***P <0.001.
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Figure 7 CHD1 and CHD2 control H3 and H3.3 occupancy at active regulatory regions. (A) Chromatin immunoprecipitation (ChIP-qPCR)
analysis of control CHD1, CHD2 and double knockdown experiments at promoters associated with DNase hypersensitivity sites (DHS) show
increased H3 occupancy with CHD1, CHD2 and double knockdowns in K562 cells. The strongest effect on H3 occupancy is observed with CHD2
knockdown. CHD2 knockdown also reduced H3.3 enrichment. (B) At intergenic and intragenic DNase sensitivity sites CHD1 and CHD2 knockdown
increase H3 occupancy with the strongest trend observed in CHD2 and double knockdown cells. As for promoter sites, CHD2 knockdown reduced
H3.3 enrichment. (C) Active tRNA loci-associated DNase sensitive sites show similar trends for both H3 and H3.3 occupancy. (D) Control loci
from nonaccessible chromatin demonstrate the effects of CHD2 knockdown on H3 and H3.3 occupancy are specific to active regions. All data
points represent mean values plotted from three biological replicates per loci tested. Differences compared to control were tested by one-way
ANOVA, *P <0.05, **P <0.01, ***P <0.001.
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matin accessibility could be to facilitate the binding of
other transcription factors and complexes. This has been
demonstrated in the case of post-initiation factors such
as the splicing machinery, whereby CHD1 promotes
efficient recruitment [47]. Interestingly accessible chro-
matin is associated with both nucleosome-free and
nucleosome containing regions and one of the strongest
correlations between chromatin accessibility and his-
tone modifications is the positioning and strength of the
H3K4me3 nucleosomes, which may act to promote
CHD1-mediated mobilization or relaxation of nucleo-
somes at regulatory regions [48].
CHD1 and CHD2 differentially affect H3 and H3.3 occupancy
One possible explanation for the effect of CHD1 on
chromatin accessibility could be through the disassembly
of nucleosomes. In fission yeast, the CHD1 homologues
Hrp1 and Hrp3 function to reduce H3 occupancy at
promoter regions [10,19]. In addition, the H3 variant
H3.3 may act to promote chromatin accessibility in
some circumstances, and CHD1 homologues in model
organisms and mammalian CHD2 have both been
linked to H3.3 deposition [12,16].
To analyze H3 occupancy and H3.3 occupancy by
ChIP-qPCR, we first tested the specificity of the total H3
and H3.3 antibodies with recombinant human H3.1 and
H3.3 proteins. The anti-H3 antibody detected both
H3.1 and H3.3, while the H3.3 specific antibody detected
only recombinant H3.3 protein by western blotting (see
Additional file 5). We then tested the performance of
these antibodies by ChIP-qPCR. When normalizing to
total H3 occupancy, which is reduced at active regions
compared to inactive regions, the relative enrichment
of H3.3 was higher at the active GAPDH promoter
compared to inactive MYOD promoter (see Additional
file 5). Similarly, at the NPM1 gene, the H3.3/H3 total
ratio was higher at the promoter compared to an intron
from the gene body (see Additional file 4).
We selected TSS, intragenic, intergenic and tRNA-
associated DHS sites, as well as a number of non-DHS
control loci. for analysis by ChIP-qPCR (Figure 7). At
TSSs, CHD1 knockdown lead to a nonsignificant trend
toward increased H3 occupancy, while CHD2 knockdownlead to a striking increase in total H3 occupancy
(Figure 7A, ***P > 0.001, one-way ANOVA). Double
CHD1 and CHD2 knockdowns showed an additive
effect with an elevated H3 occupancy compared to the
single CHD2 knockdown (Figure 7A, 3.8% input com-
pared to 4.3% input). In contrast the relative H3.3
enrichment observed in CHD2 and double CHD1 and
CHD2 knockdowns was significantly lower than that of
control and CHD1 knockdowns (Figure 7A, ***P <0.001,
**P <0.01, one-way ANOVA). Similar results were
obtained at intragenic and intergenic DHS sites with
CHD2 knockdown giving significantly elevated H3
occupancy and reduced H3.3 enrichment (Figure 7B,
*P <0.05, ****P <0.0001, one-way ANOVA). Similar
trends were also observed at active tRNA loci associ-
ated DHS for both H3 and H3.3 (H3 ***P <0.001, H3.3,
n.s. one-way ANOVA).
Surprisingly, DNase accessibility, H3 occupancy and
H3.3 enrichment do not appear to be directly related in
this study since, CHD1 affects accessibility strongly with
weaker affects on H3 occupancy, while CHD2 affects H3
occupancy and H3.3 enrichment without affecting acces-
sibility. Nucleosome occupancy is not the only factor that
regulates chromatin accessibility. Accessible chromatin
sites at intergenic loci for example show higher nucleo-
some occupancy and smaller nucleosome-free regions
than transcription start sites but are still highly accessible
[48,49]. Accessible regulatory regions are composed of
both nucleosome-free transcription factor binding sites
and adjacent accessible nucleosomes [48,49]. Hormone-
inducible transcription factors bind to nucleosome-
containing, accessible sites and are associated with
chromatin remodeling but not necessarily nucleosome
eviction [43,50]. For example, nucleosomes are present at
accessible intergenic progesterone receptor binding sites;
the ensuing progesterone receptor activation accessibility
is increased while total H3 occupancy remains unaltered
[50]. It is also possible that CHD1 depletion leads to
abnormalities in higher order chromatin structure in a
similar manner to what was demonstrated in Drosophila
polytene chromosomes, following CHD1 deletion [51].
It is perhaps less surprising that the strong increase in
H3 occupancy does not restrict chromatin accessibility
since previous studies in fission yeast revealed that hrp1
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but do not affect MNase sensitivity of promoter regions
[10,19]. One possibility is that CHD2 reduces interac-
tions of non-nucleosomal H3 with naked DNA. It also
suggests that in the absence of CHD2, other factors pre-
vent a mature and access restricting nucleosome from
forming. Reduced H3.3 occupancy following CHD2 knock-
down is likely a result of reduced CHD2-dependent
nucleosome disassembly since it has been clearly dem-
onstrated that H3.3 deposition correlates with histone
turnover at active loci [52].
Implications for the biological functions of CHD1 and CHD2
Our analysis of ChIP-seq data for the CHD1 and CHD2 in
human cells helps to reinterpret previously suggested
models of CHD1 and CHD2 recruitment. We show that
the recruitment is transcription-coupled and not driven by
H3K4me2/3 or binding to NDR regions. The primary
mechanisms of CHD1 recruitment to promoters and active
chromatin regions must be driven by interactions between
CHD1 and the mediator and must facilitate chromatin
transcription (FACT); polymerase associated factor (PAF);
and Spt-, Ada-, and Gcn5 acetyltransferase (SAGA) com-
plexes [22,38,39]. The chromodomains of CHD1 instead
act in an important post-recruitment step in the activation
and regulation of remodeling. Consistent with this notion,
chromodomain-nucleosome interactions of CHD1 regulate
DNA-dependent activation of the ATPase motor [53].
An important role of CHD1 is to facilitate Pol II
transcription through chromatin, regulating nucleosome
turnover and transcription coupled chromatin assembly
[9,18,29]. The affinity of human CHD1 for H3K4me2/3
may target the remodeling function of CHD1 to the
5’ region of active genes. For example it was recently
suggested that mammalian CHD1 plays a key role in
promoting Pol II escapes from active promoters by alle-
viating the barrier of the +1 nucleosome [29].
CHD2 has been linked to genetic stability, DNA repair
and differentiation. In muscle cell differentiation, the
myogenic transcription factor MyoD requires CHD2 for
H3.3 deposition into muscle specific gene promoters.
The strongest effects were likely seen at muscle-specific
genes in this study since these regions are heavily tran-
scribed in the model used [12]. We observe that the
H3.3 enrichment is not specific to muscle cell differenti-
ation and speculate that CHD2 is an essential enzyme
for the disassembly of H3 nucleosomes, which is a pre-
requisite for the deposition of new H3.3 during differ-
entiation. In other cell types it is possible that other
transcription factors promote the recruitment of CHD2
in an analogous manner to MyoD. The effect of CHD1
and CHD2 in particular, on H3.3 occupancy suggest
they may also play a role in the reassembly of H3.3
nucleosomes following transcription.The transcription coupled recruitment of both CHD1
and CHD2 suggest that transcription could also play a role
in noncoding regions of the genome such as promoters,
enhancers, and active tRNA loci. Previous reports have
suggested such functions for Pol II transcription at tRNA
genes, leading to the hypothesis that Pol III transcription
is facilitated by the Pol II associated machinery [34,35].
Active enhancers are also identified by Pol II transcription
[54]. In such instances, we speculate transcription may be
a mechanism for modulating chromatin structure. It was
demonstrated that another transcription-coupled, SNF2
chromatin-remodeling enzyme Brg1 (SMARCA4), was
required for enhancer activation of the MYC gene in
leukemia [55]. Another key question is how multiple re-
modeling factors determine the activity of each particular
locus. A recent study examining distinct remodeling
enzyme families demonstrated overlapping binding of
multiple remodelers to active regions [56]. Despite
redundancy at the level of genome-wide occupancy,
inactive mutants of the murine chromatin remodelers
Brg1, Chd4 and hSNF2 all regulated chromatin accessi-
bility at a subset of loci [56].
Conclusions
We conclude that CHD1 and CHD2 are recruited along
with the transcription machinery to promoters and
enhancer sites associated with transcription. For CHD1,
this establishes a clear model of recruitment via interac-
tions with Pol II-associated complexes. This provides a
basis for interpretation of previous studies and models of
CHD1 recruitment. At active regions, CHD1 and CHD2
cooperate to regulate the chromatin architecture. Thus,
transcription coupled chromatin remodeling promotes
chromatin accessibility and nucleosome disassembly at
transcribed regulatory regions.
Methods
Analysis of ENCODE data
Data from the ENCODE project were accessed and
downloaded through the UCSC web portal (http://gen-
ome.ucsc.edu/ENCODE/). The files used in this study
are listed in Additional file 6. ChIP-seq and chromatin state
data were analyzed using Seqmonk (http://www.bioinfor-
matics.babraham.ac.uk/projects/seqmonk/). All ChIP-seq
data, including CHD1 and CHD2 occupancy, was mea-
sured as the fold enrichment over input. Where indicated
in the text, differences between chromatin states were
tested for significance using the Kruskall-Wallis test with
Dunn’s post-test correction. High confidence CHD1 and
CHD2 peaks were calculated using model-based analysis
for ChIP-seq (MACS) with a stringency cut off of 1 × 10−15
and binding sites within 200 bp or less were merged [37].
MACS was used from Seqmonk version 0.27.0. For probe
trend plots calculating the enrichment of H3k4me2/3 and
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CHD2 occupancy across TSS regions, read counts were
normalized to the total number of reads and the pre-
sented as the average signal per probe.
Cell culture and drug treatment
K562 cells were cultured in RPMI 1640 medium con-
taining glutamine (Life Technologies, Stockholm,
Sweden), which was supplemented with 10% fetal bo-
vine serum, 10 U/mL penicillin and 10 U/mL strepto-
mycin (Life Technologies). To arrest transcriptional
elongation K562 cells were treated overnight (12 h)
with 100 μM 5,6-dichloro-1-β-D-ribofuranosyl-1H-benz-
imidazole (DRB) (Sigma-Aldrich, Stockholm, Sweden) or
vehicle (DMSO).
siRNA knockdown and validation
siRNA targeting CHD1 (s2974 and s2975) and CHD2
(s2979), as well as nontargeting negative controls, were
obtained from Life Technologies (Stockholm, Sweden.
K562 cells were transfected with the Neon electropor-
ation system (Life Technologies, Stockholm, Sweden;
100 ul kit). The transfection protocol was performed as
per manufacturer’s instructions with the following elec-
troporation parameters: three pulses, 1,450 v, and 10 ms
pulse width. The final total concentration of siRNA per
sample was 25 nM in 8 mL of antibiotic-free RPMI 1640
medium with 10% serum per 3 × 106 cells.
RT-qPCR
RNA from 5 × 106 K562 cells was isolated using the
RNeasy plus kit (QIAGEN, Sollentuna, Sweden). A total
of 1 μg of RNA was reverse-transcribed using Superscript™
III First Strand Synthesis Supermix (Life Technologies,
Stockholm, Sweden) according to the manufacturer’s
instructions. Resultant cDNA was diluted 1:20, and qPCR
analysis of CHD1 and CHD2 transcript abundance
was normalized to GAPDH using Taqman assays (Life
Technologies, Stockholm, Sweden; CHD1 assay ID -
Hs00154405_m1; CHD2 assay ID - Hs00172280_m1;
GAPDH assay ID - Hs02758991_g1).
Western blotting
For western blotting, 5 × 106 K562 were lyzed using sin-
gle detergent lysis buffer (50 mM Tris, 150 mM NaCl,
and 1% Triton X-100, pH 8.0) and protein concentration
was calculated using the BCA protein assay (Fisher Sci-
entific, Stockholm, Sweden). A total of 40 μg of protein
per sample was denatured and resolved on a 4 to 12% Bis-
Tris gel with MOPS running buffer (Novex, NuPAGE,
precast gels, Life Technologies, Stockholm, Sweden).
Gels were then wet-transferred to a 0.2-μM PVDF
membrane (Millipore, Solna, Sweden) at a constant
voltage of 100 V for 120 min. Membranes were air-dried, reactivated for 5 min in methanol and then
blocked for 4 h at room temperature in 5% milk in PBS
with 0.1% Tween. Membranes were incubated overnight
in primary antibodies at 1:1,000 dilution in blocking buffer
then washed three times for 10 min each in PBS 0.1%
Tween and incubated for 1 h at room temperature in
secondary antibody (GE Healthcare, Stockholm, Sweden).
Finally, the PBS-Tween washes were repeated, and the
membranes were developed with chemiluminescent
ECL substrates. Antibodies used were as follows: CHD1
(#4351, Cell Signalling Technology, Danvers, MA, USA),
CHD2 (#4170 Cell Signalling, Danvers, MA, USA), and
H3 (ab1791, Abcam, Cambridge U.K.), all at a concentra-
tion of 1:1,000.DNase accessibility
To measure chromatin accessibility, we used the
EpiQ™ chromatin analysis kit (BIORAD, Stockholm,
Sweden) according to the manufacturer’s instructions
at 28 hours post transfection with siRNA. Briefly, 0.25 ×
106 K562 cells were used per reaction and the resultant
DNA was diluted to 1 in 400 in qPCR reactions. Acces-
sibility was calculated as; 2(Ct(undigested)-Ct(digested)). We
then normalized each loci to the percentage of acces-
sibility in control siRNA treated cells. Primers were
designed to DNase hypersensitivity peaks in K562 cells
based on ENCODE data. For TSS, DHS regions we
focused on expressed genes, whereas for intragenic
and intergenic regions, we selected DHS sites observed
when looking for accessible and inaccessible TSS re-
gions. For tRNA loci, we chose loci from expressed
tRNA genes that did not overlap with an annotated
TSS but did overlap with a DHS. Primers are listed in
Additional file 7.ChIP qPCR
K562 cells were fixed in 1% paraformaldehyde for 8 mi-
nutes, and ChIP was performed using the iDeal ChIP-
seq kit (Diagenode, Liege, Belgium) according to the
manufacturer’s instructions. Chromatin extracts from
one million cells were sonicated to yield 100 to 500 bp
fragments using a Bioruptor™ Plus (Diagenode) on high
power for two rounds of 12 cycles with 30s on 30s off
at 4°C. Antibodies used in ChIP were as follows; CHD1 -
3 μl per reaction of #4351 (Cell Signalling Technology,
Danvers, MA, USA), CHD2 - 3 μl per reaction of ab68301
(Abcam, Cambridge U.K.), H3 - 2 μl per reaction of
ab1791 (Abcam, Cambridge U.K.), and H3.3 - 3 μl per
reaction of 09–838 (Millipore, Solna, Sweden). Primers
for qPCR were designed across DNase hypersensitivity
sites at TSS regions, intergenic or intragenic regions,
or active tRNA loci and are listed in Additional file 7:
Table S2.
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Additional file 1: CHD7 occupancy at promoter chromatin states in
K562 and H1 embryonic stem cells (ESCs). The occupancy of CHD7
was calculated as the fold enrichment over input.
Additional file 2: Recruitment of CHD1 and CHD2 to active tRNA
loci. (A) The occupancy of CHD1 and CHD2 across BRF1 and BRF2 binding
sites in K562 cells was calculated as the fold enrichment over input. (B) A
selected, expressed tRNA gene in an intergenic region showing BRF1, CHD1,
CHD2 and Pol II occupancy in K562 cells.
Additional file 3: Average enrichment of Pol II, Pol II ser2, CHD1
and CHD2 at transcribed genes. Transcribed genes were identified as
in the top quintile of Pol II ser 2 occupancy and analyzed for Pol II, CHD1
and CHD2 enrichment across the gene plus 2.5 kb up and downstream.
Additional file 4: CHD1 and CHD2 siRNA knockdown. (A) Transcript
abundance of CHD1 and CHD2 relative to GAPDH in K562 cells 48 h
following siRNA transfection. (B) Western blot analysis of CHD1 and CHD2
expression 72 h following transfection.
Additional file 5: Analysis of H3.3 antibody specificity by western
blot and ChIP-qPCR. (A) The reactivity of total H3 and H3.3 specific
antibodies toward 10 to 250 ng of recombinant human H3.1 and H3.3
was analyzed by western blot. (B) The relative enrichment of H3.3 to total
H3 was examined by ChIP qPCR at active GAPDH and inactive MYOD
gene TSS and the active NPM1 promoter and NPM1 intron.
Additional file 6: ENCODE data files used.
Additional file 7: Primers for qPCR.
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